文献速递神经肿瘤

奥曲肽治疗脑膜瘤:体外研究、临床相关性及文献综述

Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.
PubMed 文献 · J Neurosurg · 2016-12-16

该研究在80例脑膜瘤(含31例WHO II级和4例WHO III级)原代细胞培养中分析奥曲肽的体外效应,发现SST2 mRNA在100%受检脑膜瘤中检出,奥曲肽在88%脑膜瘤中显著降低细胞增殖但不诱导细胞死亡。文献Meta分析显示奥曲肽对WHO I级肿瘤有兴趣,尤其是颅底肿瘤6个月无进展生存率达92%。

要点

  • 奥曲肽在体外仅作为抗增殖剂,不促进脑膜瘤细胞凋亡。
  • SST2 mRNA在100%受检脑膜瘤中检出,水平与其他表达SST2的肿瘤相似。
  • 文献Meta分析显示WHO I级颅底脑膜瘤6个月无进展生存率达92%。

核心结论

  • 奥曲肽在体外仅作为抗增殖剂,不促进脑膜瘤细胞凋亡;因此体内奥曲肽可能限制肿瘤生长而非诱导肿瘤缩小。

研究设计与样本

  • 研究分析80例脑膜瘤的新鲜原代细胞培养,包括31例WHO II级和4例WHO III级肿瘤,研究奥曲肽对细胞活力、凋亡和信号转导通路的影响。

主要发现

  • SST2 mRNA在100%受检脑膜瘤中检出,水平与其他表达SST2的肿瘤、神经内分泌肿瘤或垂体腺瘤相似。
  • 奥曲肽在88%脑膜瘤中显著降低细胞增殖,但不诱导细胞死亡。
  • 平均而言,高SST2水平脑膜瘤组的细胞增殖抑制程度高于低SST2组。
  • 奥曲肽反应与merlin蛋白水平正相关,与磷酸化p70-S6激酶水平负相关。
  • 奥曲肽抑制Akt磷酸化并激活酪氨酸磷酸酶,不影响ERK通路。

关键数值与推荐

  • 文献Meta分析显示奥曲肽对WHO I级肿瘤治疗有兴趣,尤其是颅底肿瘤6个月无进展生存率达92%。
  • 生长抑素类似物耐受性良好,可能作为侵袭性脑膜瘤的共靶向治疗。

临床怎么用

  • 作者认为奥曲肽在体内可能限制肿瘤生长而非诱导肿瘤缩小。
  • 作者指出生长抑素类似物可能作为侵袭性脑膜瘤的共靶向治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE Meningiomas express somatostatin receptor subtype 2 (SST2), which is targeted by the somatostatin analog octreotide. However, to date, using somatostatin analog therapy for the treatment of these tumors in clinical practice has been debated. This study aims to clarify the in vitro effects of octreotide on meningiomas for precise clinical applications. METHODS The effects of octreotide were analyzed in a large series of 80 meningiomas, including 31 World Health Organization (WHO) Grade II and 4 WHO Grade III tumors, using fresh primary cell cultures to study the impact on cell viability, apoptosis, and signal transduction pathways. RESULTS SST2 mRNA was detected in 100% of the tested meningiomas at levels similar to those observed in other SST2-expressing tumors, neuroendocrine tumors, or pituitary adenomas. Octreotide significantly decreased cell proliferation in 88% of meningiomas but did not induce cell death. On average, cell proliferation was more inhibited in the meningioma group expressing a high level of SST2 than in the low-SST2 group. Moreover, octreotide response was positively correlated to the level of merlin protein and inversely correlated to the level of phosphorylated p70-S6 kinase, a downstream effector of the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway. Octreotide inhibited Akt phosphorylation and activated tyrosine phosphatase without impacting the extracellular regulated kinase (ERK) pathway. CONCLUSIONS Octreotide acts exclusively as an antiproliferative agent and does not promote apoptosis in meningioma in vitro. Therefore, in vivo, octreotide is likely to limit tumor growth rather than induce tumor shrinkage. A meta-analysis of the literature reveals an interest in octreotide for the treatment of WHO Grade I tumors, particularly those in the skull base for which the 6-month progression-free survival level reached 92%. Moreover, somatostatin analogs, which are well-tolerated drugs, could be of interest for use as co-targeting therapies for aggressive meningiomas.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Graillon T, Romano D, Defilles C, et al. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. J Neurosurg. 2016. PMID: 27982767. doi:10.3171/2016.8.JNS16995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。